ATE374753T1 - 3-(2,4)dihydroxyphenyl-4-phenylpyrazole und deren medizinische verwendung - Google Patents
3-(2,4)dihydroxyphenyl-4-phenylpyrazole und deren medizinische verwendungInfo
- Publication number
- ATE374753T1 ATE374753T1 AT02805823T AT02805823T ATE374753T1 AT E374753 T1 ATE374753 T1 AT E374753T1 AT 02805823 T AT02805823 T AT 02805823T AT 02805823 T AT02805823 T AT 02805823T AT E374753 T1 ATE374753 T1 AT E374753T1
- Authority
- AT
- Austria
- Prior art keywords
- sub
- sup
- compounds
- independently
- hsp90
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 5
- 101710113864 Heat shock protein 90 Proteins 0.000 abstract 4
- 125000003118 aryl group Chemical group 0.000 abstract 4
- 238000011282 treatment Methods 0.000 abstract 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 150000002148 esters Chemical class 0.000 abstract 2
- 230000001404 mediated effect Effects 0.000 abstract 2
- -1 oxycarbonyloxy Chemical group 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 125000004423 acyloxy group Chemical group 0.000 abstract 1
- 125000003368 amide group Chemical group 0.000 abstract 1
- 150000001408 amides Chemical class 0.000 abstract 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 150000002170 ethers Chemical class 0.000 abstract 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 abstract 1
- 125000003831 tetrazolyl group Chemical group 0.000 abstract 1
- 150000003568 thioethers Chemical class 0.000 abstract 1
- 125000003396 thiol group Chemical group [H]S* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/16—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0130733A GB0130733D0 (en) | 2001-12-21 | 2001-12-21 | Therapeutic compounds and their use in therapy |
| GB0225688A GB0225688D0 (en) | 2002-11-04 | 2002-11-04 | Therapeutic compounds and their use in therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE374753T1 true ATE374753T1 (de) | 2007-10-15 |
Family
ID=26246898
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02805823T ATE374753T1 (de) | 2001-12-21 | 2002-12-19 | 3-(2,4)dihydroxyphenyl-4-phenylpyrazole und deren medizinische verwendung |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7247734B2 (de) |
| EP (1) | EP1456180B1 (de) |
| JP (1) | JP4399265B2 (de) |
| AT (1) | ATE374753T1 (de) |
| AU (1) | AU2002356301A1 (de) |
| DE (1) | DE60222804T2 (de) |
| WO (1) | WO2003055860A1 (de) |
Families Citing this family (103)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1671379A (zh) | 2001-11-30 | 2005-09-21 | Qlt公司 | 亚肼基吡唑衍生物和它们作为治疗剂的用途 |
| US6770597B2 (en) * | 2002-07-17 | 2004-08-03 | Ishihara Sangyo Kaisha, Ltd. | Benzohydrazide derivatives as herbicides and desiccant compositions containing them |
| ES2385378T3 (es) | 2002-07-24 | 2012-07-24 | Dermira (Canada), Inc. | Derivados de pirazolilbenzotiazol y su uso como agentes terapéuticos |
| US7427616B2 (en) | 2002-08-06 | 2008-09-23 | Astrazeneca Ab | Condensed pyridines and pyrimidines with tie2 (TEK) activity |
| WO2004014886A1 (en) * | 2002-08-07 | 2004-02-19 | University Of Mississippi | Antigiardial agents and use thereof |
| GB0228417D0 (en) * | 2002-12-05 | 2003-01-08 | Cancer Rec Tech Ltd | Pyrazole compounds |
| GB0229618D0 (en) * | 2002-12-19 | 2003-01-22 | Cancer Rec Tech Ltd | Pyrazole compounds |
| DK1611112T3 (da) * | 2003-02-11 | 2012-11-19 | Cancer Res Inst | Isoxazolforbindelser som hæmmere af varmechokproteiner |
| CN101333192A (zh) | 2003-04-03 | 2008-12-31 | 默克公司 | 作为钠通道阻滞剂的联芳基取代吡唑 |
| GB0309637D0 (en) * | 2003-04-28 | 2003-06-04 | Cancer Rec Tech Ltd | Pyrazole compounds |
| GB0313915D0 (en) * | 2003-06-16 | 2003-07-23 | Smithkline Beecham Corp | Compounds |
| WO2005063222A1 (ja) * | 2003-12-26 | 2005-07-14 | Kyowa Hakko Kogyo Co., Ltd. | Hsp90ファミリー蛋白質阻害剤 |
| BRPI0506760A (pt) * | 2004-01-09 | 2007-05-22 | Novartis Ag | derivados de fenil-[4-(3-fenil-1h-pirazol-4-il)-pirimidin-2-il]-amina como inibidores de igf-ir |
| GB0402518D0 (en) | 2004-02-05 | 2004-03-10 | Astrazeneca Ab | Therapeutic agents |
| WO2005110963A1 (en) * | 2004-05-19 | 2005-11-24 | Cellzome Ag | (biphenyl-3-yl)-carboxylic acids and derivatives thereof and their use in therapy |
| EP1604970A1 (de) * | 2004-05-19 | 2005-12-14 | Cellzome Ag | 2-(Biphenyl-3-yl)-carbonsäuren mit gamma-Sekretase-modulierender Wirkung |
| DE102004039280A1 (de) * | 2004-08-13 | 2006-02-23 | Merck Patent Gmbh | 1,5-Diphenyl-pyrazole |
| RU2375384C2 (ru) | 2004-09-22 | 2009-12-10 | Ниппон Каяку Кабусики Кайся | Новый блок-сополимер, мицеллярный препарат и противораковое средство, включающее мицеллярный препарат в качестве активного ингредиента |
| DE102004049078A1 (de) | 2004-10-08 | 2006-04-13 | Merck Patent Gmbh | Phenylpyrazole |
| ME01498B (me) | 2004-11-18 | 2014-04-20 | Synta Pharmaceuticals Corp | Jedinjenja triazola koja modulišu aktivnost hsp90 |
| TW200639163A (en) * | 2005-02-04 | 2006-11-16 | Genentech Inc | RAF inhibitor compounds and methods |
| DE102005007304A1 (de) | 2005-02-17 | 2006-08-24 | Merck Patent Gmbh | Triazolderivate |
| CN101123954B (zh) * | 2005-02-21 | 2011-07-13 | 协和发酵麒麟株式会社 | 抗肿瘤剂 |
| DE102005009440A1 (de) | 2005-03-02 | 2006-09-07 | Merck Patent Gmbh | Thienopyridinderivate |
| US8399464B2 (en) | 2005-03-09 | 2013-03-19 | Nippon Kayaku Kabushiki Kaisha | HSP90 inhibitor |
| WO2006095783A1 (ja) | 2005-03-09 | 2006-09-14 | Nippon Kayaku Kabushiki Kaisha | 新規なｈｓｐ９０阻害剤 |
| EP1877379B1 (de) | 2005-04-13 | 2013-01-16 | Astex Therapeutics Limited | Hydroxybenzamidderivate und ihre verwendung als hsp90-inhibitoren |
| EP1891028A1 (de) * | 2005-05-18 | 2008-02-27 | Forschungsverbund Berlin e.V. | Nicht-peptidische inhibitoren der akap-pka-wechselwirkung |
| FR2885904B1 (fr) * | 2005-05-19 | 2007-07-06 | Aventis Pharma Sa | Nouveaux derives du fluorene, compositions les contenant et utilisation |
| US7473784B2 (en) * | 2005-08-01 | 2009-01-06 | Bristol-Myers Squibb Company | Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors |
| AU2006279794B2 (en) * | 2005-08-12 | 2011-04-07 | Synta Pharmaceuticals Corp. | Pyrazole compounds that modulate HSP90 activity |
| TWI446910B (zh) | 2005-08-18 | 2014-08-01 | Synta Pharmaceuticals Corp | 調節ｈｓｐ９０活性的三唑化合物 |
| NL2000351C2 (nl) | 2005-12-22 | 2007-09-11 | Pfizer Prod Inc | Estrogeen-modulatoren. |
| WO2007092496A2 (en) * | 2006-02-07 | 2007-08-16 | Conforma Therapeutics Corporation | 7,9-dihydro-purin-8-one and related analogs as hsp90-inhibitors |
| US7754725B2 (en) | 2006-03-01 | 2010-07-13 | Astex Therapeutics Ltd. | Dihydroxyphenyl isoindolymethanones |
| JP2009530261A (ja) * | 2006-03-16 | 2009-08-27 | ファイザー・プロダクツ・インク | ピラゾール化合物 |
| US8323669B2 (en) | 2006-03-28 | 2012-12-04 | Nippon Kayaku Kabushiki Kaisha | Polymer conjugate of taxane |
| DE102006023336A1 (de) * | 2006-05-18 | 2007-11-22 | Merck Patent Gmbh | 1,5-Diphenyl-pyrazole II |
| WO2007135910A1 (ja) | 2006-05-18 | 2007-11-29 | Nippon Kayaku Kabushiki Kaisha | ポドフィロトキシン類の高分子結合体 |
| EP2026797A2 (de) * | 2006-05-25 | 2009-02-25 | Synta Pharmaceuticals Corporation | Verfahren zur behandlung von non-hodgkin-lymphom |
| WO2007139951A2 (en) * | 2006-05-25 | 2007-12-06 | Synta Pharmaceuticals Corp. | Method for treating proliferative disorders associated with protooncogene products |
| CA2653329C (en) | 2006-05-25 | 2018-01-16 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate hsp90 activity |
| AR061185A1 (es) | 2006-05-26 | 2008-08-13 | Chugai Pharmaceutical Co Ltd | Compuestos heterociclicos como inhibidores de hsp90. composiciones farmaceuticas. |
| US20090239782A1 (en) | 2006-10-03 | 2009-09-24 | Masaharu Nakamura | High-molecular weight conjugate of resorcinol derivatives |
| GB0620259D0 (en) | 2006-10-12 | 2006-11-22 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| US8883790B2 (en) | 2006-10-12 | 2014-11-11 | Astex Therapeutics Limited | Pharmaceutical combinations |
| WO2008044027A2 (en) | 2006-10-12 | 2008-04-17 | Astex Therapeutics Limited | Pharmaceutical compounds having hsp90 inhibitory or modulating activity |
| US8277807B2 (en) | 2006-10-12 | 2012-10-02 | Astex Therapeutics Limited | Pharmaceutical combinations |
| EP2073803B1 (de) | 2006-10-12 | 2018-09-19 | Astex Therapeutics Limited | Pharmazeutische kombinationen |
| US9730912B2 (en) | 2006-10-12 | 2017-08-15 | Astex Therapeutics Limited | Pharmaceutical compounds |
| EP2080779B1 (de) | 2006-11-06 | 2016-05-18 | Nippon Kayaku Kabushiki Kaisha | Polymeres derivat eines nucleinsäuremetabolismus-antagonisten |
| JP5548365B2 (ja) | 2006-11-08 | 2014-07-16 | 日本化薬株式会社 | 核酸系代謝拮抗剤の高分子誘導体 |
| DE102007002715A1 (de) | 2007-01-18 | 2008-07-24 | Merck Patent Gmbh | Triazolderivat |
| ATE553107T1 (de) | 2007-03-01 | 2012-04-15 | Chugai Pharmaceutical Co Ltd | Makrocyclische verbindung |
| CA2680161A1 (en) | 2007-03-05 | 2008-09-12 | Kyowa Hakko Kirin Co., Ltd. | Pharmaceutical composition |
| US8993608B2 (en) | 2007-03-12 | 2015-03-31 | Synta Pharmaceuticals Corp. | Method for inhibiting topoisomerase II |
| EA201000113A1 (ru) * | 2007-08-01 | 2010-08-30 | Пфайзер Инк. | Пиразольные соединения |
| WO2009026658A1 (en) * | 2007-08-29 | 2009-03-05 | The University Of Sydney | Ppar agonists |
| EP2200653A2 (de) | 2007-09-10 | 2010-06-30 | University of Massachusetts | Antitumorale mittel gegen mitochondrien |
| USRE46190E1 (en) | 2007-09-28 | 2016-11-01 | Nippon Kayaku Kabushiki Kaisha | High-molecular weight conjugate of steroids |
| EP2258397B1 (de) | 2008-03-18 | 2017-10-11 | Nippon Kayaku Kabushiki Kaisha | Polymerkonjugat aus einem physiologisch aktiven stoff |
| GB0806527D0 (en) | 2008-04-11 | 2008-05-14 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| US9149540B2 (en) | 2008-05-08 | 2015-10-06 | Nippon Kayaku Kabushiki Kaisha | Polymer conjugate of folic acid or folic acid derivative |
| WO2010001989A1 (ja) * | 2008-07-03 | 2010-01-07 | 協和発酵キリン株式会社 | 癌幹細胞及び／または癌前駆細胞の減少剤並びに癌の再発及び／または転移の予防剤 |
| BRPI0916356B1 (pt) | 2008-07-24 | 2022-08-23 | Nerviano Medical Sciences S.R.L | 3,4-diaril pirazois como inibidores da proteína quinase |
| EP2151433A1 (de) | 2008-08-05 | 2010-02-10 | Institut Pasteur | Alkoxypyrazole und Verfahren zu ihrer Herstellung |
| EP2151434A1 (de) | 2008-08-05 | 2010-02-10 | Institut Pasteur | Allkoxypyrazole und Verfahren zu ihrer Herstellung |
| EP2406216B1 (de) * | 2009-03-11 | 2017-04-19 | Bayer Intellectual Property GmbH | Halogenalkylmethylenoxy-phenyl-substituierte ketoenole |
| JP5731479B2 (ja) | 2009-04-21 | 2015-06-10 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | Ｈｓｐ９０阻害剤としてのレゾルシノール誘導体 |
| WO2010131675A1 (ja) | 2009-05-15 | 2010-11-18 | 日本化薬株式会社 | 水酸基を有する生理活性物質の高分子結合体 |
| EP3205647B1 (de) * | 2009-08-17 | 2020-05-13 | Memorial Sloan-Kettering Cancer Center | 2-(pyrimidin-5-yl)-thiopyrimidine derivate als hsp70 and hsc70 modulatoren zur behandlung von proliferativen erkrankungen |
| AR077975A1 (es) | 2009-08-28 | 2011-10-05 | Irm Llc | Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina |
| US20120283120A1 (en) | 2009-09-29 | 2012-11-08 | Takeda Pharmaceutical Company Limited | Screening method |
| ES2737429T3 (es) | 2009-10-07 | 2020-01-14 | Karo Pharma Ab | Pirazoles sustituidos como ligandos del receptor de estrógenos |
| EA023942B1 (ru) * | 2010-01-27 | 2016-07-29 | НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. | Сульфонамидные производные 3,4-диарилпиразолов в качестве ингибиторов протеинкиназы |
| US20120309750A1 (en) * | 2010-02-17 | 2012-12-06 | Ildong Pharm Co., Ltd. | 5-membered heterocycle derivatives and manufacturing process thereof |
| US9205086B2 (en) | 2010-04-19 | 2015-12-08 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of a Hsp90 inhibitory compounds and a EGFR inhibitor |
| EP2601185B1 (de) | 2010-08-03 | 2015-10-07 | Nerviano Medical Sciences S.r.l. | Derivate aus pyrazolphenyl-benzolsulfonamid-verbindungen und ihre verwendung als antitumorwirkstoffe |
| WO2012067138A1 (ja) | 2010-11-17 | 2012-05-24 | 日本化薬株式会社 | 新規なシチジン系代謝拮抗剤の高分子誘導体 |
| GB201113538D0 (en) | 2011-08-04 | 2011-09-21 | Karobio Ab | Novel estrogen receptor ligands |
| ES2635117T3 (es) | 2011-09-11 | 2017-10-02 | Nippon Kayaku Kabushiki Kaisha | Método para la fabricación de un copolímero de bloques |
| WO2013067165A1 (en) | 2011-11-02 | 2013-05-10 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitors with platinum-containing agents |
| CA2853799A1 (en) | 2011-11-02 | 2013-05-10 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors |
| BR112014011223A8 (pt) | 2011-11-11 | 2023-01-31 | Novartis Ag | Método de tratar uma doença proliferativa |
| US9402831B2 (en) | 2011-11-14 | 2016-08-02 | Synta Pharmaceutical Corp. | Combination therapy of HSP90 inhibitors with BRAF inhibitors |
| KR102091295B1 (ko) | 2011-11-23 | 2020-03-19 | 어레이 바이오파마 인크. | 제약 제제 |
| CN103183640B (zh) * | 2011-12-30 | 2016-04-27 | 沈阳药科大学 | 二芳基吡唑类化合物及其制备方法与用途 |
| US20140079636A1 (en) * | 2012-04-16 | 2014-03-20 | Dinesh U. Chimmanamada | Targeted therapeutics |
| DE102013012685A1 (de) * | 2013-07-31 | 2015-02-05 | Johann-Wolfgang-Goethe Universität Frankfurt am Main | Arylierte Pyrazolderivate und deren Verwendung als Fluoreszenzfarbstoffe |
| CN104974091B (zh) * | 2014-04-10 | 2018-01-02 | 沈阳药科大学 | 3‑甲基‑1,5‑二芳基吡唑类化合物及其制备方法和用途 |
| EP3143013B1 (de) | 2014-05-13 | 2019-12-18 | Memorial Sloan Kettering Cancer Center | Hsp70-modulatoren und verfahren zu ihrer herstellung und verwendung |
| FR3022244B1 (fr) * | 2014-06-17 | 2016-07-01 | Centre Nat De La Rech Scient (Cnrs) | Utilisation d'un nouveau compose 3-aryl-4-catechol-pyrrole-n-propanol et ses derives pour le traitement du cancer et des pathologies associees a une angiogenese excessive |
| US10035792B2 (en) * | 2015-01-22 | 2018-07-31 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Resorcinol derivative as HSP90 inhibitor |
| GB201706806D0 (en) | 2017-04-28 | 2017-06-14 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| CA3067572A1 (en) | 2017-06-20 | 2018-12-27 | Madrigal Pharmaceuticals, Inc. | Targeted therapeutics |
| US11491145B2 (en) | 2017-06-20 | 2022-11-08 | Madrigal Pharmaceuticals, Inc. | Combination therapies comprising targeted therapeutics |
| EP3801587A4 (de) * | 2018-06-05 | 2022-08-10 | Flagship Pioneering Innovations V, Inc. | Acylierte catechinpolyphenole und verfahren zu deren verwendung zur behandlung von krebs |
| CN109134204B (zh) * | 2018-11-16 | 2022-03-08 | 棓诺(苏州)新材料有限公司 | 中间体2-溴-4-氟-5-氯苯酚的合成法 |
| CN110283080A (zh) * | 2019-07-05 | 2019-09-27 | 山西大学 | 一种含氟的二苯甲酮衍生物及其制备方法和应用 |
| EP3827825A1 (de) * | 2019-11-26 | 2021-06-02 | Wageningen Universiteit | Neuartige verwendung von 3,4-diarylpyrazolen als antibakterielle mittel |
| AU2021339844A1 (en) * | 2020-09-14 | 2023-05-04 | Genzyme Corporation | Compounds as modulators of bis-phosphoglycerate mutase for the treatment of sickle cell disease |
| WO2023004280A1 (en) * | 2021-07-19 | 2023-01-26 | The Board Of Trustees Of The Leland Stanford Junior University | Selective pyrazole lrrk2 inhibitors and methods for use thereof |
| CN120623147B (zh) * | 2025-08-01 | 2025-12-16 | 广东省科学院动物研究所 | 吡唑喹啉醚类化合物及其在制备神经保护药物中的应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5559137A (en) | 1994-05-16 | 1996-09-24 | Smithkline Beecham Corp. | Compounds |
| US5486534A (en) | 1994-07-21 | 1996-01-23 | G. D. Searle & Co. | 3,4-substituted pyrazoles for the treatment of inflammation |
| CA2288741A1 (en) * | 1997-05-22 | 1998-11-26 | G.D. Searle And Co. | 4-aryl-3(5)-heteroaryl substituted pyrazoles as p38 kinase inhibitors |
| ES2281186T3 (es) * | 1998-08-07 | 2007-09-16 | Novartis Vaccines And Diagnostics, Inc. | Pirazoles como moduladores de receptores de estrogenos. |
| AU1199600A (en) * | 1998-10-02 | 2000-04-26 | Board Of Trustees Of The University Of Illinois, The | Estrogen receptor ligands |
| WO2002066462A1 (en) * | 2001-02-02 | 2002-08-29 | Glaxo Group Limited | Pyrazole derivatives against tgf overexpression |
| GB0102687D0 (en) | 2001-02-02 | 2001-03-21 | Pharmacia & Upjohn Spa | Oxazolyl-pyrazole derivatives active as kinase inhibitors,process for their preparation and pharmaceutical compositions comprising them |
| JP2005022972A (ja) | 2001-05-16 | 2005-01-27 | Teikoku Hormone Mfg Co Ltd | ４−（４−ピリダジニル）ピラゾール誘導体 |
-
2002
- 2002-12-19 AT AT02805823T patent/ATE374753T1/de not_active IP Right Cessation
- 2002-12-19 AU AU2002356301A patent/AU2002356301A1/en not_active Abandoned
- 2002-12-19 US US10/499,030 patent/US7247734B2/en not_active Expired - Fee Related
- 2002-12-19 JP JP2003556391A patent/JP4399265B2/ja not_active Expired - Fee Related
- 2002-12-19 EP EP02805823A patent/EP1456180B1/de not_active Expired - Lifetime
- 2002-12-19 WO PCT/GB2002/005778 patent/WO2003055860A1/en not_active Ceased
- 2002-12-19 DE DE60222804T patent/DE60222804T2/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JP4399265B2 (ja) | 2010-01-13 |
| US7247734B2 (en) | 2007-07-24 |
| DE60222804T2 (de) | 2008-07-03 |
| EP1456180A1 (de) | 2004-09-15 |
| AU2002356301A1 (en) | 2003-07-15 |
| WO2003055860A1 (en) | 2003-07-10 |
| DE60222804D1 (de) | 2007-11-15 |
| EP1456180B1 (de) | 2007-10-03 |
| US20050222230A1 (en) | 2005-10-06 |
| JP2005517675A (ja) | 2005-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60222804D1 (de) | 3-(2,4)dihydroxyphenyl-4-phenylpyrazole und deren medizinische verwendung | |
| NO991700L (no) | Benzimidazol-2-karbamater for behandling av virusinfeksjoner og cancer | |
| AU2003225617A1 (en) | Thiadiazolylpiperazine derivatives useful for treating or preventing pain | |
| WO2002030879A3 (en) | Carbamic acid compounds comprising a sulfonamide linkage as hdac inhibitors | |
| PH12021551256A1 (en) | Pantetheine derivatives and uses thereof | |
| GB9426103D0 (en) | Therapeutic agents | |
| IL142257A0 (en) | Amide derivatives, process for their preparation, compositions containing them and use thereof in the manufacture of a medicament for the treatment of cytokine-mediated diseases | |
| PT828724E (pt) | Diaril-5-oxigenadas-2-(5h)-furanonas comoinibidoras de cox-2 | |
| ATE360630T1 (de) | Azabicyclische heterocyclen als modulatoren des cannabinoidrezeptors | |
| IL133585A0 (en) | Soluble prodrugs of paclitaxel | |
| NZ246202A (en) | Amidino-substituted alpha-amino acid derivatives and pharmaceutical compositions | |
| BR0206955A (pt) | Ligantes de receptores de canabinóides | |
| MX2007004183A (es) | Derivados de benzoimidazol utiles como agentes antiproliferacion. | |
| DE60211935D1 (de) | Alkandiol derivate zur behandlung von knochenkrankheiten | |
| NO20040589L (no) | Arylsulfonylderivater med 5-HT6 reseptor affinitet. | |
| ATE330928T1 (de) | Substituierte chalkone als arzneimitteln | |
| NO20004162D0 (no) | Antitumor agens | |
| IL108695A (en) | Pharmaceutical composition comprising polyamine derivatives and some such novel compounds | |
| TNSN05246A1 (en) | Use of 10-hydroxy-10, 11-dihydrocarbamazepine derivatives for the treatment of affective disorders | |
| HUP0104308A2 (hu) | Amidino- és guanidino-azetidinon-származékok, mint triptáz inhibitorok, eljárás előállításukra, ezeket tartalmazó gyógyszerkészítmények, valamint intermedierek | |
| PT871626E (pt) | Triazolonas utilizadas como inibidores de sintese da apoliproteina b | |
| US20110151025A1 (en) | Compositions Comprising N-Halogenated or N,N-Dihalogenated Amine for Treatment and Prophylaxis of Bronchopulmonary Infections | |
| MY129537A (en) | Amino acid ester containing azole antifungals | |
| CA2367138A1 (en) | Anti-inflammatory uses of manzamines | |
| EA200600022A1 (ru) | Применение производных бицикло [2.2.1] гептана для приготовления нейропротекторных фармацевтических композиций |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |